Analysts suspected that the mid-stage trial miss wouldn't ding Neurocrine’s share price since expectations around the program ...
The COLA boost is slightly better than earlier estimates, even if we're not talking about a lot of money. But many retirees ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback